-
Mirum Pharmaceuticals NASDAQ:MIRM Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.
Location: | Website: mirumpharma.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.931B
Cash
278.4M
Avg Qtr Burn
-5.858M
Short % of Float
19.89%
Insider Ownership
2.21%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LIVMARLI (Maralixibat) Details Chronic pruritus, Alagille syndrome | Approved Quarterly sales | |
LIVMARLI (Maralixibat) Details Liver disease, Progressive familial intrahepatic cholestasis | Approved Quarterly sales | |
Chenodal® (chenodiol) Details Cerebrotendinous xanthomatosis | NDA Acceptance for review | |
LIVMARLI (Maralixibat) Details Bile duct disease, Rare diseases | Phase 2b Update | |
Volixibat (VANTAGE) Details Primary biliary cholangitis, Liver disease | Phase 2b Update | |
Volixibat (VISTAS) Details Liver disease, Primary sclerosing cholangitis | Phase 2b Update | |
Volixibat (OHANA) Details Liver disease, Intrahepatic Cholestasis of Pregnancy | Failed Discontinued |